C-reactive protein (CRP) is an acute phase protein implicated in the progression of cancer. A positive correlation between tumour stage and plasma CRP levels was demonstrated in prostate cancer, indicating a relationship between raised CRP levels and more aggressive disease, suggesting a role for inflammatory response in tumour progression. Aim of this study was to assess the tumoural presence and cellular location of CRP and establish if these are linked to clincopathological features of the cohort and patient survival. Tissue microarray technology was employed to analyse 50 matched pairs of hormone sensitive and refractory prostate cancers. Immunohistochemistry was performed using antibody to CRP. CRP was assessed using the weighted histoscore method. CRP presence was observed in the cytoplasm and nucleus of selected tumours. Cytoplasmic CRP correlated positively with metastases at diagnosis (P ¼ 0.039), whereas nuclear CRP presence correlated with metastases at relapse (P ¼ 0.006). A trend towards an increase in cytoplasmic and nuclear CRP presence from hormone sensitive to hormone refractory tumours was noticed. No significant association between tumoural CRP presence, time to biochemical relapse or disease-specific survival was observed. Tumoural CRP is likely to have a role in progression of prostate cancer, as it is associated with increased presence of metastases at the time of diagnosis and time of relapse. A larger powered study is necessary to establish if CRP presence is associated with disease-specific survival.
Introduction
Prostate cancer has the highest incidence and the second highest mortality of any cancer affecting UK males. While the 5-year relative survival for organ-confined prostate cancer is over 90%, for locally advanced or metastatic disease, it is only around 30%. 1 The mainstay of treatment for locally advanced or metastatic prostate cancer is androgen deprivation therapy. 2 Unfortunately, this therapy is only effective for a median of 18 months, following which the patients relapse and the tumours are able to grow in a castrate environment. 3 At this stage, they are termed castrate resistant (CRPC). Currently, there is no definitive curative treatment for castrateresistant prostate cancers; 2 however, taxane therapy can extend survival for a median time period of 3 months.
C-reactive protein (CRP) is an acute phase protein implicated in the progression of prostate cancer. CRP is a member of the pentraxin family and composed of five identical polypeptide units, which confer a very high stability to the molecule. Plasma CRP is mainly produced by hepatocytes in response to inflammatory cytokines, particularly interleukin (IL)-6 and IL-1. Due to its high stability, CRP has a relatively long plasma half-life of 19 h, and is a naive systemic marker of inflammation. 4, 5 Elevated plasma CRP levels are found in many disease processes including infection, myocardial infarction and malignancies. 5 Elevated circulating CRP levels have been shown to be linked to poor prognosis in several cancers including multiple myeloma, melanoma, lymphoma, ovarian, renal, pancreatic, lung and gastrointestinal tumours. 6 In metastatic and castrate-resistant prostate cancer, elevated plasma CRP levels have been recorded and shown to be independent predictors of poor survival and to be associated with a lower probability of response to chemotherapy. 7, 8 A positive correlation between tumour stage and plasma CRP levels has been demonstrated in both renal cell carcinoma and prostate cancer. 7, 8 This indicates a relationship between raised CRP levels and more aggressive disease, suggesting a role for inflammatory response in tumour progression. But as yet the mechanism for this is unexplained.
It is hypothesised that CRP exerts its effect via activation of nuclear factor (NF)-kB pathway. NF-kB presence has been linked with invasion and metastasis in prostate cancer and has been shown to be upregulated in castrate-resistant prostate cancer.
3,9 NF-kB is also believed to have a proinflammatory role; its activation in tumour-associated inflammatory cells has been shown to contribute to tumour growth by inducing synthesis of tumour promoting proinflammatory mediators. 10 In vitro evidence from human hepatoma cell lines also suggests a link between NF-kB and CRP, suggesting that NF-kB participates in CRP production. Other work done in hepatoma cell lines and coronary artery smooth muscle cells looking at IL-17 stimulation of CRP production again showed this relationship between NF-kB and CRP. 11 Recent work has shown that CRP levels are not only increased systemically but also locally within the tumour. Jabs et al. 8 showed that circulating CRP levels correlated with CRP mRNA expression in renal cell carcinoma and Nozoe et al. 12 has provided immunohistochemical evidence of CRP production by squamous cell carcinoma of the oesophagus. The origin of this 'tumour CRP' is poorly explained.
This study seeks to determine the relationship between tumoural CRP presence, interrelationship to clinicopathological features of the patient cohort and cancerspecific survival in the progression of prostate cancer from hormone naive to castrate-resistant tumours.
Materials and methods

Patient cohort
Ethics approval was granted to this study by the Scottish multi-centre research ethics committee.
Patients with matched hormone naive and castrateresistant tumour samples were retrospectively selected for analysis. To be selected for the study, patients had to have initially responded to hormone deprivation therapy, defined as a decrease of PSA level of 50%, and then gone on to relapse, described as two consecutive rises in PSA level of over 10%. A pre-and post-sample had to be available for analysis. Pre-hormone naive samples were obtained from patients diagnosed with locally advanced or metastatic prostate cancer who received surgery followed by androgen deprivation or maximum androgen blockade therapy. The hormone naive samples were obtained from a TURP or transrectal ultrasonographyguided biopsy. Patients then had to relapse. Post-hormone samples could only be collected if patients required TURP to relieve clinical symptoms (for example bladder outflow obstruction). This tissue was then utilised to construct a tissue microarray (TMA).
TMA construction
TMAs were already available for use in the current study. Two 0.6 mm 2 cores of lowest and highest Gleason grade prostate cancer tissue, identified by the pathologist, were removed from representative areas of the tumour taken from prostate cancer patients. All TMA blocks were constructed in duplicate. For missing samples and samples not on the TMA due to insufficient tissue, 4 mm sections taken from the original paraffin blocks were used.
Immunohistochemistry anti-CRP
Sections were dewaxed and rehydrated through a series of xylene and alcohol washes. Heat-mediated antigen retrieval was performed in Tris-EDTA buffer (pH 8) for 20 min in a Dako microwave. Sections were incubated in 5% blocking solution at 25 1C for 20 min before being incubated in 1:100 dilution of primary antibody at 25 1C for 2 h. The primary antibody for detecting CRP was rabbit monoclonal [Y284] to CRP (Abcam plc., Cambridge, UK). Antibody antigen binding was detected using the peroxidase-based Envision (Dako, Cambridgeshire, UK) technique using a diaminobenzidine chromogenic substrate system. Sections were then counterstained using Haematoxylin, dehydrated and mounted in DPX. In each run, a positive and negative isotype matched control was included to ensure no false-positive staining.
Immunohistochemistry scoring
Protein presence of each core (four per tumour specimen) was assessed using the weighted histoscore method. The weighted histoscore method grades staining intensity as negative (0), weak (1), moderate (2) and strong (3) and then multiplies the percentage of tumour cells within each category by the number assigned to that category (0, 1, 2 or 3, respectively). 13 The histoscore ranges from 0 (minimum) to 300 (maximum). All TMAs were scored independently by two observers for their nuclear and cytoplasmic protein staining within each tumour core. Agreement between observers was good and measured in interclass correlation coefficient. All interclass correlation coefficient scores were 40.7.
Western blot
Western blots were performed to ensure the specificity of the antibody used in the immunohistochemistry study. 
Statistical analysis
Wilcoxon signed rank tests were used to compare CRP presence between androgen naive and androgen innaive tumours. Kaplan-Meier curves generated time to relapse, time to death from relapse and disease-specific C-reactive protein presence in progressive prostate cancer B Elsberger et al survival rates. The log rank test was used to compare significant differences between subgroups using univariate analysis. A P-value of 0.05 was deemed to be significant. Data are expressed as median and range. The statistical analyses were performed using a statistical software package (SPSS 15.0, Chicago, IL, USA).
Results
Clinicopathological details of patient cohort
The cohort consisted of 50 patients. Matched data pairs were available for 42 patients.
At initial diagnosis, the median age of patients was 70 years (interquartile range 65.5-73.0 years). Median Gleason score was 7.0 (interquartile range 6.5-9.0) and 15 patients (35.7%) had metastases. Median time to biochemical relapse from diagnosis was 2.59 years (interquartile range 1.67-4.05 years) and median overall survival was 4.39 years (interquartile range 3.34-6.74 years). Patients with locally advanced (66%) or metastatic prostate cancer (34%) subsequently received surgery and androgen deprivation therapy (14 subcapsular bilateral orchidectomy, 27 gonadotropin-releasing hormone analogue and 1 had both). Twenty-nine of the 42 patients also received anti-androgen therapy and this included all those who received gonadotropin-releasing hormone analogues. On univariate analysis, tumoural PSA expression (Po0.001) was associated with shorter time to biochemical relapse and overall survival was associated with the presence of metastases at relapse (P ¼ 0.013).
During the period of follow-up, 36 patients died of their cancer, a further 10 patients died of intercurrent disease, 1 patient was lost to follow. At the end of the follow-up period, 3 patients were still alive. Correlations between the clinicopathological characteristics of this cohort are shown in Tables 1a and b. CRP presence in hormone naive prostate tumours Due to tissue limitation, CRP presence was successfully assessed in 86% of hormone naive tumour samples (43/50). From this 86%, 79.1% (34/43) exhibited cytoplasmic and 27.9% (12/43) nuclear CRP presence (Figure 2a ). Tumours were subdivided into high or low presence of CRP according to median values of the protein being assessed. w 2 analysis was then performed to assess correlation between clinical parameters and protein presence (Table 1a) . Presence of CRP in the (Figure 2b ). Again tumours were subdivided into high or low CRP presence according to median values of the protein being assessed. w 2 analysis was then performed to assess correlation between clinical parameters and protein presence (Table 1b) . Nuclear CRP presence correlated with metastases at relapse (P ¼ 0.006; Table 1b ).
Change in CRP presence in the transition from hormone naive to castrate-resistant disease In order to determine if levels of CRP presence changed in the transition from hormone naive prostate cancer to castrate-resistant disease, boxplots were constructed and levels were compared hormone naive tumours to castrate-resistant tumours using the Wilcoxon signed ranks tests. While these results did not reach significance, there was a trend towards an increase in the presence of cytoplasmic and nuclear CRP noted (Figures 3a and b) .
As the hormone naive and castrate-resistant tumour samples are matched in this cohort, it was possible to analyse changes of CRP levels in pre-and post-hormone escape on an individual patient basis. In order for a change in CRP presence to be deemed significant, the difference had to be 450. This value was chosen as it is the threshold used to judge acceptable levels of interobserver variability and is unlikely to be a chance finding. This information can then be used to divide patients into those with a decrease in CRP presence, those with no change and those with an increase.
Survival analysis
Kaplan-Meier survival curves were generated and log rank tests were performed to assess if the presence of CRP within the tumour was related to time to relapse or disease-specific survival in hormone naive prostate cancer or time to death from relapse or disease-specific survival in castrate-resistant prostate cancer. Again, CRP presence was divided into high or low according to median values. No significant association was seen in the hormone naive prostate cancer patient cohort between CRP presence, time to biochemical relapse (cyto-CRP P ¼ 0.392, nuc-CRP P ¼ 0.998; Figures 4a and b) and disease-specific survival (cyto-CRP P ¼ 0.0.830, nuc-CRP Increased CRP presence in the cytoplasm was noticed in four patients, whereas two patients showed a decrease in cytoplasmic CRP. However, the majority of patients (n ¼ 26) had no significant changes in CRP presence in the cytoplasm. None of the patients showed a significant change in the presence of CRP in the nucleus. Therefore, C-reactive protein presence in progressive prostate cancer B Elsberger et al due to the low patient numbers demonstrating significant changes in tumoural CRP presence, survival analysis was not performed.
Discussion
Currently, it is hypothesised that CRP has an important role in the progression of prostate cancer and is associated with a more aggressive and invasive phenotype. The results of the current study demonstrate that cytoplasmic CRP in hormone naive tumours significantly correlates with the presence of metastases at cancer diagnosis. Serum levels of CRP have previously been linked with metastases in prostate cancer. 14 This present study also established a correlation between metastases at relapse and nuclear CRP presence.
To our knowledge, there is currently no literature available examining the cellular location of CRP in prostate tumour specimens. It is not established if cellular location of CRP influences clinical outcome of prostate cancer patients. Multiple proteins (Akt, NF-kB, inhibitor-kappa B kinase a) are known to have diverse roles in different locations of the cell. Src kinase, when activated at tyrosine site 419, and highly expressed in breast cancer tissue at cellular membrane is associated with shorter disease-specific survival. 15 In order to study the role of CRP in the progression of prostate cancer, CRP presence was assessed before and after progression of the tumour. There was no statistically significant difference between CRP presence before and after castrate resistance. However, there was a trend towards increased CRP presence in castrate-resistant prostate cancer specimens noted. This could be likely due to low patient numbers and warrants further work in expanding the patient cohort.
There are limitations of examining the biology of the primary tumour versus its metastases. It would be of interest to investigate CRP presence and expression profile of primary tumours with matched metastasis to provide insight regarding change of CRP. Recent literature suggests that the cancer's biology at its metastatic sites differs from the primary tumour. Erin et al. 16 found altered gene expression in breast cancer liver metastasis, whereas Koo et al. 17 established different immunohistochemical breast cancer phenotypes expression according to metastatic site. Not just the potential dissimilar biology of the primary to the metastasis needs to be considered, but also the possibility that metastatic sites may be even more predictive of prostate cancer patients' clinical outcome than primary tumours.
No significant association was seen between CRP presence within the tumour and disease-specific survival. This is most likely due to this study being underpowered to detect significant associations with survival. The majority of available literature relating high CRP expression with decreased survival uses serum levels of CRP to correlate with patient survival. 18 Recent work has shown that CRP levels are not only increased systemically but also locally within the tumour. Jabs et al. 8 showed that circulating CRP levels correlated with CRP mRNA expression in renal cell carcinoma and Nozoe et al. 12 has provided immunohistochemical evidence of CRP production by squamous cell carcinoma of the oesophagus. The origin of this 'tumour CRP' is unclear. It has been suggested that the tumour is responsible for increased IL-6 production, which correlates with CRP production. 18, 19 However McArdle et al. 19, 20 propose an alternative explanation, suggesting that the source of the IL-6 is the host inflammatory cells rather than the tumour. Indeed, increased CD4 þ T-lymphocyte infiltration in prostate cancer has been associated with poor cancer-specific survival, independent of stage. 10 We have performed RT-PCR for CRP in 10 clinical prostate specimens and have used liver tissue as a positive control in this study mRNA CRP was undetectable in prostate tumour samples (unpublished results). This therefore suggests that the tumour cells are taking up CRP from their surrounding environment rather producing it.
The role of tumoural presence of CRP or even tumour expression of CRP, which was predicted to be linked to survival, is a relatively novel concept. Low patient numbers and small range of histoscores made classification of patients into sufficiently large subgroups for statistical analysis difficult and could be possible reasons why this study did not show a significant association between relapse, survival and CRP presence in prostate tumours.
Conclusions
This study demonstrates that tumoural CRP presence is likely to have a role in progression of prostate cancer, being associated with the presence of metastases at the time of diagnosis and time of relapse. However, this study does not show a significant association between tumoural CRP presence, biochemical relapse and patient survival. CRP presence in this cohort fails to predict time to relapse or disease-specific survival. Despite of this, CRP remains key potential target as driver of cancer progression. Further work is required in a larger cohort to definitively determine the association of tumoural presence and location of CRP, biochemical relapse and survival, to explore the relationship between serum CRP and presence of CRP within the tumour itself and to elucidate the possible roles of involved signalling pathways.
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